Background. The maximum plasma concentration (Cmax) of oxymorphone extended release (ER) 20 mg and 40 mg is approximately 50% higher in fed than in fasted subjects, with most of the difference in area-under-the-curve (AUC) occurring in the first 4 hours post-dose. Hence, the US FDA recommends in the approved labeling that oxymorphone ER is taken at least 1 hour before or 2 hours after eating.
Introduction
Oxymorphone is a semi-synthetic μ-opioid-receptor agonist approved for the treatment of moderate-to-severe pain. It is available in an extended release (ER) formulation for patients who require around-the-clock opioid for a prolonged period of time [1] . The pharmacokinetics of the TimeRx ® formulated available ER doses (5, 10, 20, 30 , and 40 mg) was determined in single-dose and steadystate conditions in healthy volunteers [2] . The results show linear, dose-dependent plasma concentrations for the medication and its metabolites, with the maximum concentrations achieved approximately 3 hours after administration of a single dose.
The effects of food on the bioavailability of single doses of oxymorphone ER were determined in two studies in healthy volunteers. After administration of 20 mg or 40 mg, the studies revealed that the maximum plasma concentrations (Cmax) are increased by approximately 50% in fed versus fasted subjects, with most of the difference in area-under-the-curve (AUC) occurring in the first 4 hours post-dose [3] . Hence, the US Food and Drug Administration (FDA) recommends in the approved labeling that oxymorphone ER is taken at least 1 hour before or 2 hours after eating.
The objective of the present study is to determine whether 40 mg oxymorphone ER, the highest single dose available of the medication, taken after a high-fat meal impacts cognition in opioid-tolerant subjects any differently than when taken fasting. Cognitive performance was assessed using a subset of tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) [4] : Rapid Visual Information Processing (RVP), Spatial Recognition Memory (SRM), and Spatial Working Memory (SWM). The underlying hypothesis is that 40 mg oxymorphone ER taken with food, resulting in higher maximum plasma concentrations than fasting, impacts cognitive performance. The opioid-tolerant subjects who participated in the study were taking opioids long term for chronic nonmalignant pain, mostly low back and/or joint pain.
Methods

Study Design
This is a single-site, randomized, rater-blinded, crossover study in 30 opioid-tolerant subjects of the effect of a single dose of 40 mg oxymorphone ER, fed versus fasting, on cognitive performance. The study was approved by Asentral Institutional Review Board in Salisbury, Massachusetts, and all subjects gave written informed consent before any study-related procedures were performed.
Inclusion/Exclusion Criteria
The men and women included in the study were 18 to 70 years old and 100 to 300 pounds in weight. They had chronic nonmalignant pain treated around-the-clock with opioids. The subjects were opioid tolerant in the sense that each received no less than 90 days of opioid therapy prior to screening. In terms of oral morphine equivalent, the minimum allowable dose was 90 mg, with an overall average of 207 mg per day (median: 180 mg per day; range: 90 mg to 502 mg per day). For transdermal fentanyl, a minimum dose of 50 mcg per hour was required (1,200 mcg per day) [5] . For comparison, the "FDA-endorsed" definition of opioid tolerant is 60 mg oral morphine equivalent per day or 25 mcg per hour when transdermal fentanyl is used. Opioid conversions were performed using GolbalRPh, an easily accessible and commonly used online opioid conversion calculator (http://www.GlobalRPh.com). Potential variability exists for opioid conversions, and we are especially cognizant of such issues with methadone, particularly converting doses that exceed 30 mg orally per day. However, the conversions as performed in the study only served the purpose of determining the opioid tolerant status of the subjects. The daily opioid dose was stable for at least 1 week prior to screening. Exclusion criteria were: 1) pregnancy, nursing, or planning to become pregnant; 2) gastrointestinal disorder, such as delayed gastric emptying, or recent gastrointestinal surgery, such as partial or complete gastrectomy, which might impact absorption of study medication; 3) alcohol or substance abuse within 2 years of screening; 4) impaired liver function, defined as transaminase levels greater than three times the upper limit of normal; 5) impaired kidney function, defined as an estimated creatinine clearance of less than 50 ml/min; 6) Epworth Sleepiness Scale (ESS) score of 16 or higher; 7) contraindications to oxymorphone, including hypersensitivity to the medication or other morphine analogs; 8) acute or severe bronchial asthma or hypercarbia; 9) hypertension (≥160/ 100 mm Hg) or unstable cardiovascular illness; 10) intake of mixed agonist-antagonist opioid analgesics, anticholinergics, cimetidine, or central nervous system depressants (hypnotics, antipsychotics, tricyclics, tetracyclics, lithium, anticonvulsants, monoamine-oxidase inhibitors), unless the medications had been stable in dose for at least 1 month prior to screening; and 11) exposure to an investigational medication within 30 days of screening.
Procedures
The study comprised three visits, a screening visit and two testing visits. The screening visit consisted of informed consent, vital signs, medical history, concomitant medications, physical examination, ESS, urine pregnancy test in all women of child-bearing potential, hematology, blood chemistry, including alcohol level, and urine drug screen for cocaine. Furthermore, the subjects were familiarized with the CANTAB tests through a training session.
After completion of the screening process and assuring eligibility in terms of inclusion/exclusion criteria, the subjects were randomized to determine at which testing visit a high-fat meal was to be consumed. They were instructed not to eat or drink, except for water, after midnight on the night before testing, not to consume alcohol within 24 hours of testing and xanthine-containing beverages (coffee, tea, coca cola, energy drinks, etc.) on the morning of the testing. Subjects who were taking an oral opioid were instructed not to take their morning dose on the days of testing, and those who used the transdermal fentanyl patch were instructed not to change the patch the night before.
Each testing visit consisted of an assessment of adversehealth and concomitant-medication changes and also a blood alcohol draw, followed by a high-fat breakfast, if applicable. Under supervision, the subjects took the study medication, a single dose of 40 mg oxymorphone ER, with water. Cognitive performance was assessed 1 hour and 3 hours post-dose using three CANTAB tests as described below.
High-Fat Meal
The meal was a predetermined selection of items from the McDonald's ® (McDonald's Corporation, Chicago, IL, USA) breakfast menu and consisted of an 8-oz 1% low-fat milk jug, a portion of hash brown, two sausage patties, an order of scrambled eggs, and a regular size biscuit. Its caloric value is approximately 1,010 kCal, coming from 65 grams of fat, 63 grams of carbohydrates, and 42 grams of protein.
Cambridge Neuropsychological Test Automated Battery (CANTAB) [4]
At both testing visits, cognitive performance was assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB). The subjects were comfortably seated at a distance of approximately 0.5 m from the monitor. They were instructed to carry out the tasks by touching the screen or using a response box. After an initial explanation and successfully completing a simple motor-screening task (touching the center point of flashing crosses on the screen), the subjects performed the following tests: 1) RVP; 2) SRM; and 3) SWM. A detailed description of the tests is beyond the scope of this article and can be found in the CANTAB manual and on the following website: http://www.cantab.com/cantabtests.asp. Here, only a brief description of the tests is presented, along with the outcome measures used.
RVP is a test of sustained attention. It is a sensitive measure of general cognitive performance. A white box appears in the center of the computer screen, inside which digits, from 2 to 9, appear in a pseudorandom order, at the rate of 100 digits per minute. The subject is requested to detect target sequences of three digits (for example, 2-4-6, 3-5-7, 4-6-8) and to register responses using the response box. The two main outcome measures are the probability to detect the predefined sequence (sensitivity [A′]) and the speed at which the sequence is registered (response latency [ms]).
SRM tests visual spatial recognition memory in a twochoice forced discrimination paradigm. The subject is presented with a white square, which appears in sequence at five different locations on the screen. In the recognition phase, the subject sees a series of five pairs of squares, one of which is in a place previously seen in the presentation phase. The other square is in a location not seen in the presentation phase. Locations are tested in the reverse of the presentation order. The two main outcome measures are the percentage of correct trials (correct hits [%] ) and the speed of the subject's response (response
SWM is a test of the subject's ability to retain spatial information and to manipulate remembered items in working memory. It is a self-ordered task, which also assesses heuristic strategy. The test is a sensitive measure of executive function. It begins with a number of colored squares (boxes) being shown on the screen. By touching the boxes and using a process of elimination, the subject finds blue tokens in a number of boxes and uses them to fill up an empty column on the screen. The number of boxes is gradually increased, until it is necessary to search a total of eight boxes. The color and position of the boxes are changed from trial to trial to discourage the use of stereotyped search strategies. The two main outcome measures are errors (touching boxes that have been found to be empty and revisiting boxes that have already been found to contain a token (total errors) and a measure of strategy (strategy score).
Statistical Analysis
The results of the CANTAB tests were analyzed using a repeated-measure analysis of variance (ANOVA) model with the within-subject factors food (fed versus fasting) and time post-dose (1 hour versus 3 hours). In this model, an effect of the factor food suggests that fed versus fasting significantly impacts the effects of 40 mg oxymorphone ER on cognition, while an effect of the factor time post-dose suggests that the medication influences cognition differently at 1 hour and 3 hours postdose. We also tested for an effect of the interaction food × time post-dose to determine whether fed versus fasting influences the differences in cognitive performance 1 hour and 3 hours post-dose. Age and gender were used as between-subject factors to assess potential confounding effects. The a priori sample-size estimation for a power of 80% with α = 0.05 was based on the primary outcome measure, the RVP sensitivity (A′) score. Using a repeatedmeasure ANOVA for the food effect (fed versus fasting) and assuming an effect size of f = 0.26 generated a required sample size of 32 subjects. However, early termination of the study for logistic reasons resulted in 30 subjects completing both testing visits, generating a power of 78.2%.
Results
Thirty subjects (17 men and 13 women) with chronic, nonmalignant pain and treated daily with opioids completed the study. Their ages ranged from 32 to 71 years with a mean of 50.2 ± 8.7 (SD) years. Their conditions and opioid use, including average total daily doses, actual and in mg morphine equivalent, are shown in Table 1 . The chronic pain conditions included low-back pain in two thirds of the subjects. The most common opioids used were oxycodone (16 subjects) and methadone (12 subjects), followed by morphine and fentanyl (five subjects each).
The effects of 40 mg oxymorphone ER on the main outcome measures of the three CANTAB tests used, that is, RVP sensitivity (A′) (probability), RVP response latency (ms), SRM correct hits (%), SRM response latency (ms), SWM total errors, and SWM strategy score, after fasting for 8 to 12 hours and after a high-fat meal, 1 and 3 hours post-dose are shown in Table 2 and Figure 1 . Full factorial analysis revealed no significant impact (P > 0.05) of age or gender on any of the outcome measures and, therefore, these variables were not included as covariates in the further analysis. The factor food, testing fed versus fasting, also did not generate significant effects on any of the outcome measures (Table 3) . However, repeated-measure ANOVA revealed a significant time post-dose effect for RVP: sensitivity (A′) (F[1,28] = 22.71; P < 0.001; η 2 = 0.45) and response latency (F[1,28] = 14.05; P < 0.001; η 2 = 0.33), as well as for SRM (response latency: F [1, 28] = 31.26; P < 0.001; η 2 = 0.53). These performance effects are likely attributed to learning because they were not affected by food intake and were significantly better 3 hours post-dose. In addition, RVP showed a significant food × time post-dose interaction effect (F[1,28] = 6.88; P = 0.01; η 2 = 0.20), indicating that 40 mg oxymorphone ER in the fed condition was associated with less signal detection 1 hour post-dose than fasting. However, no significant difference in signal detection was found in fed versus fasting 3 hours post-dose.
Discussion
In healthy, opioid-naïve subjects and as expected, opioids negatively impact cognition, as demonstrated, among others, by Jensen et al. [6] and Cherrier et al. [7] Jensen et al. studied 23 healthy male volunteers, who were administered 0.6 mg buprenorphine intravenously, a semisynthetic, mixed μ-opioid-receptor agonist-antagonist. Cognition was tested with the trail-making test for visual information processing, the finger-tapping test for psychomotor speed, and continuous reacting time for attention. The medication was found to cause significant deficits in cognitive and psychomotor performance, with a half-life of 1-1.5 hours. Cherrier et al. studied 71 middle-aged and older healthy volunteers, who were administered 10 mg immediate-release (IR) oxycodone in a placebocontrolled, crossover trial. They observed significant declines in simple and sustained attention, working memory, and verbal memory at 1 hour post-dose compared to baseline, with a tendency for return to baseline by 5 hours post-dose.
Negative impact of immediate-release opioids has also been demonstrated in patients on chronic (>6 months) opioid treatment. Kamboj et al. [8] conducted a doubleblind, placebo-controlled, crossover study to assess the impact of IR morphine on cognition in 14 patients receiving palliative care. The patients took a mean daily dose of 190.7 mg morphine equivalent (range: 30-800 mg per day) and were given an average IR morphine dose of 25.6 mg (range: 5-100 mg, with most patients receiving 20 mg). They displayed antegrade memory impairment Table 2 Descriptive statistics of the effects of 40 mg oxymorphone ER, after fasting for 8-12 hours and after a high-fat meal 1 hour and 3 hours post-dose, on the CANTAB tests: RVP, SRM, and SWM after IR morphine relative to placebo and also had significant "retrograde" memory impairment, that is, they exhibited delayed recall of information presented before the IR morphine was administered. In addition, the IR morphine reduced performance on a complex tracking task, while enhancing it on a simpler tracking task. The latter may be due to the improvement of pain following the IR morphine administration, which in an electrophysiological study was suggested as the explanation of the improved perceptualcognitive status, following sustained-release morphine treatment for 1 to 2 weeks in six patients with severe nonmalignant pain [9] . , and SWM (E and F), after fasting for 8 to 12 hours and after a high-fat meal, 1 hour and 3 hours post-dose. In the graphs, the means are displayed ± 1 standard error of the mean (SEM).
Cognitive impairment due to pain is also suggested by a study of 14 patients with cancer pain receiving opioids for their pain and 12 patients receiving pain treatment without opioids [10] . The patients treated without opioids performed better in the reverse-order Digit Span Test and the clock-drawing test than those treated with opioids, but the differences arose in just one assessment in each case, suggesting opioid use not to be associated with significant cognitive impairment. In the patients receiving opioids, pain intensity correlated negatively with scores on the Mini-Mental State Examination (MMSE) and on some of the Brief Cognitive Screening Battery tests (incidental recall, immediate recall, and late recall). They found opioid dose not to correlate with any of the measures of cognitive performance but, instead, observed that the patients with the worst performance were those with the more intense pain. A similar observation was made in a study of 1,009 patients with chronic nonmalignant pain, of whom 889 were receiving opioids for their pain in an average daily dose of 92 mg morphine equivalent [11] . The Medical Outcomes Study Mental Health Inventory (MOS-MHI) cognitive-functioning scale indicated poorer cognition in the chronic pain patients, as compared to a general clinic sample. However, there were limited differences in the MOS-MHI scores between the chronic pain patients on daily opioids versus those on intermittent opioids and those receiving no opioids at all. When a regression model was applied to the data, the results suggested psychological measures and pain intensity to be more predictive of decrements in cognition than specific opioid preparations or daily opioid use. On the other hand, in a study of 1,915 cancer patients treated with opioids for moderate or severe pain for at least 3 days, those receiving daily opioid doses of 400 mg or more morphine equivalent had 1.75 times higher odds of having lower MMSE scores, compared to those receiving daily doses of less than 80 mg [12] .
Actual improvement in cognition with adequate opioid pain control was observed in a study of 84 patients with chronic nonmalignant pain inadequately controlled with short-acting opioid analgesics [13] . The patients were treated with ER morphine at an average daily dose of 59.1 mg (range: 15-360 mg per day), with more than 80% taking a daily dose of 60 mg or less. After 4 weeks of treatment, a statistically significant improvement in cognitive performance test scores from baseline was observed for short-term recall, motor function, ability to focus and maintain visual attention, sustained attention, and information processing.
In our study, we did not look at the effects of opioids on cognition per se or at the effects of opioid treatment of pain on cognitive performance but at the impact of a high-fat meal on the cognitive effects of 40 mg oxymorphone ER, as compared to taking the medication on an empty stomach, that is, after a fast of 8 to 12 hours. We assessed cognition through three tests of a test battery referred to as CANTAB, which are: RVP, SRM, and SWM. The first test is considered a sensitive measure of general cognitive performance and the third one of executive function, while the second one is a memory and learning test. A food effect was not observed for any of the three tests, suggesting that whether taken with or without food, oxymorphone's effects on cognitive performance are similar. RVP and SRM showed a time post-dose effect, suggesting a learning effect with regards to these tests from 1 hour to 3 hours post-dose. This learning effect was mitigated by the oxymorphone for RVP but only when the medication was taken after a high-fat meal, suggesting a minor impact on cognitive performance fed versus fasting. Confirming studies are needed, as well as studies to measure other aspects of functional performance, but we have to reject our hypothesis that 40 mg oxymorphone ER taken with food impacts cognitive performance. 
